Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy

Trial suggests patients with a low test score could be treated with hormone therapy alone with near-identical outcomes

• Like Christmas': woman's relief after test finds she can skip chemotherapy

Millions of women with breast cancer could be spared chemotherapy with a groundbreaking genomic test, according to the results of a trial that could transform healthcare guidelines worldwide.

Treatment for breast cancer, the world's most prevalent form of the disease, involves surgery to remove tumours. Chemotherapy is then usually recommended when doctors believe there is a risk the disease will return.